Janus Henderson Global Life Sciences Fund is a registered fund series of JANUS INVESTMENT FUND (series S000010494). Net assets $5.2B as of 2026-03-31.
Showing 15 of 104 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Eli Lilly & Co. | — | $459.4M | 883.94% |
| Johnson & Johnson | — | $378.9M | 729.12% |
| AstraZeneca PLC | — | $238.6M | 459.15% |
| AbbVie Inc. | — | $210.5M | 405.07% |
| UnitedHealth Group Inc. | — | $162.7M | 313.03% |
| Novartis AG | — | $148.4M | 285.56% |
| Thermo Fisher Scientific Inc | — | $130.4M | 250.88% |
| Praxis Precision Medicines Inc | — | $127.3M | 244.85% |
| Argenx SE | — | $124.7M | 240.03% |
| Abbott Laboratories | — | $124.5M | 239.52% |
| Bridgebio Pharma Inc | — | $115.2M | 221.63% |
| Roche Holding AG | — | $114.9M | 221.07% |
| Sanofi SA | — | $107.7M | 207.27% |
| Vertex Pharmaceuticals Incorporated | — | $107.1M | 206.14% |
| Revolution Medicines Inc | — | $105.8M | 203.59% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $5.2B |
| 2025-12-31 | $5.4B |
| 2025-09-30 | $4.6B |
| 2025-06-30 | $4.4B |
| 2025-03-31 | $4.7B |
| 2024-12-31 | $4.8B |
| 2024-09-30 | $5.7B |
| 2024-06-30 | $5.5B |